Eli Lilly and Co (LLY)
550.27
+0.14
(+0.03%)
USD |
NYSE |
Sep 22, 14:32
Eli Lilly Enterprise Value: 538.31B for Sept. 21, 2023
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 21, 2023 | 538.31B |
| September 20, 2023 | 556.83B |
| September 19, 2023 | 561.88B |
| September 18, 2023 | 558.39B |
| September 15, 2023 | 562.55B |
| September 14, 2023 | 577.69B |
| September 13, 2023 | 584.59B |
| September 12, 2023 | 584.99B |
| September 11, 2023 | 581.44B |
| September 08, 2023 | 572.80B |
| September 07, 2023 | 560.24B |
| September 06, 2023 | 547.63B |
| September 05, 2023 | 545.96B |
| September 01, 2023 | 544.94B |
| August 31, 2023 | 542.18B |
| August 30, 2023 | 536.28B |
| August 29, 2023 | 541.89B |
| August 28, 2023 | 541.91B |
| August 25, 2023 | 541.65B |
| August 24, 2023 | 536.29B |
| August 23, 2023 | 541.38B |
| August 22, 2023 | 541.66B |
| August 21, 2023 | 538.24B |
| August 18, 2023 | 534.80B |
| August 17, 2023 | 526.47B |
| Date | Value |
|---|---|
| August 16, 2023 | 534.62B |
| August 15, 2023 | 534.98B |
| August 14, 2023 | 526.80B |
| August 11, 2023 | 517.57B |
| August 10, 2023 | 510.98B |
| August 09, 2023 | 515.62B |
| August 08, 2023 | 511.23B |
| August 07, 2023 | 447.13B |
| August 04, 2023 | 442.78B |
| August 03, 2023 | 442.46B |
| August 02, 2023 | 447.51B |
| August 01, 2023 | 446.19B |
| July 31, 2023 | 447.57B |
| July 28, 2023 | 451.31B |
| July 27, 2023 | 447.99B |
| July 26, 2023 | 446.66B |
| July 25, 2023 | 450.41B |
| July 24, 2023 | 452.10B |
| July 21, 2023 | 454.68B |
| July 20, 2023 | 456.37B |
| July 19, 2023 | 446.63B |
| July 18, 2023 | 444.39B |
| July 17, 2023 | 440.54B |
| July 14, 2023 | 442.74B |
| July 13, 2023 | 428.73B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
116.30B
Minimum
Oct 10 2019
584.99B
Maximum
Sep 12 2023
229.78B
Average
200.87B
Median
May 17 2021
Enterprise Value Benchmarks
| Amgen Inc | 171.40B |
| Biogen Inc | 37.70B |
| Johnson & Johnson | 407.64B |
| Merck & Co Inc | 301.41B |
| Pfizer Inc | 206.30B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.763B |
| Revenue (Quarterly) | 8.312B |
| Total Expenses (Quarterly) | 5.974B |
| EPS Diluted (Quarterly) | 1.95 |
| Gross Profit Margin (Quarterly) | 78.26% |
| Profit Margin (Quarterly) | 21.21% |
| Earnings Yield | 1.29% |
| Operating Earnings Yield | 1.67% |
| Normalized Earnings Yield | 1.414 |